Skip to main content

Jessica Hagen

Jessica Hagen
By Jessica Hagen | 01:35 pm | December 11, 2025
Genentech will leverage Medra's Physical AI, Scientific AI and robotics into its lab systems to accelerate drug discovery.
By Jessica Hagen | 12:11 pm | December 10, 2025
The report shows that enterprise AI adoption has surged, with healthcare among the fastest‑growing sectors at 8x year‑over‑year adoption.
By Jessica Hagen | 10:53 am | December 10, 2025
CLEAR's biometric ID verification will be added to Welldoc's cardiometabolic care app, a move the companies say supports federal efforts to build a more connected health ecosystem.
By Jessica Hagen | 04:38 pm | December 08, 2025
According to healthcare leaders, 2025 was a pivotal year for AI and digital health, marked by technological progress, a shifting focus on its role in healthcare and practical use cases driving its adoption.
By Jessica Hagen | 03:00 pm | December 08, 2025
The company will use the funds to advance product innovation, strengthen clinical partnerships and accelerate its nationwide growth.
By Jessica Hagen | 01:04 pm | December 08, 2025
Alongside the acquisition, the two companies entered a multi-year partnership to cross-integrate their platforms, aiming to expand access to clinical trials.
By Jessica Hagen | 08:00 am | December 08, 2025
The partnership will allow employers to purchase Noom directly through the healthcare navigation company beginning in the first quarter of 2026.
By Jessica Hagen | 12:45 pm | December 05, 2025
Angle Health raises $134 million, and Trial Library secures $10 million.
By Jessica Hagen | 04:52 pm | December 04, 2025
Charles N. Kahn III, president and CEO of the Federation of American Hospitals and cofounder of Future of Health, discusses inconsistent and diminishing federal data collection and the urgent need to rebuild trust in the public health sector.
By Jessica Hagen | 01:56 pm | December 04, 2025
Industry leaders say 2025 marked AI’s shift from hype to practical impact, though the technology remains unready for full-scale adoption and ongoing concerns about ethics and bias persist.